If FDA approves the combination tablet, it will bring together the distinct mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
FDA action extends Kuvan’s market exclusivity to June 2015 and is based on trials submitted in response to a written request by the FDA to investigate the use
The company is seeking approval of the fixed-dose combination (FDC) tablet for use in combination with other antiretroviral agents to treat patients with HIV-1. Developed by Gilead Sciences,
The previous clinical trials have showed that the new therapeutic option for the standard therapy of patients with hormone-resistant tumors reduces the risk of death by about 35%.
The Phase III research study was double blind, randomized, and placebo-controlled study designed to assess the efficacy of Dysport.. The study, which enrolled 243 patients, was conducted in
ThioBridge was developed by PolyTherics for site-specific conjugation of cytotoxic payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has two antibody technology platforms, which
With the acquisition, Bio-Rad will expand its Digital Biology Center as well as establish a research and development site in Cambridge, Massachusetts. GnuBIO has developed a DNA sequencing
IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug. In the resubmitted NDA, the company has provided updated safety and stability information.
The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are important to the therapeutic application of human induced pluripotent stem cells
Zertane is an oral drug currently in late-stage development as a proprietary treatment for premature ejaculation, a condition that has a major impact on the quality of life
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.